Even as BAT expands beyond trial criteria, patients see gains in LVEF, symptoms, and more. A survival impact remains unclear.

Comprehensive Enterprise Evidence-Based Patient Activation Intelligence Solution Connects Healthcare Value-Based Care Strategy to Measurable Results Across Access, Referral Closure, Care Transitions, ...

The family and friends of the teen whose body was found behind a South Wilkes-Barre garage last month have started a petition ...

Did Israel use its Iron Beam laser defence system to intercept Hezbollah rockets? Here’s what is confirmed, what remains ...

Leerink Partners Global Healthcare Conference March 8 - 11, 2026 in Miami, FL Fireside chat on March 9 at 9:20 AM ET InflaRx will also conduct one-on-one investor meetings on March 9th. A link to view ...

PurpleLab enables activation with leading identity and audience providers, including LiveRamp, OpenAP, and Experian, supporting campaigns across screens and platforms, where audiences are most engaged ...

Suchandrima Bhowmik has written over 300 articles on various health conditions, medical news, and recent breakthroughs. Her work appears in several publications, including Medical News Today, ...

Complement 3 glomerulopathy (C3G) is a rare kidney disease that is also considered an autoimmune disorder. There is no single cure for C3G, but several treatments may slow disease progression, protect ...

There are two types of complement 3 glomerulopathy: dense deposit disease (DDD) and C3 glomerulonephritis (C3GN). DDD often begins earlier in life and may progress more quickly. Both are linked to an ...

Department of Rheumatology, Toronto University, Toronto, ON, Canada. Department of Rheumatology, Toronto University, Toronto, ON, Canada. Department of Internal Medicine, Qatif Central Hospital, Qatif ...

Aptamer Group plc, a developer of next-generation synthetic binders for the life sciences industry, has signed a new therapeutic development agreement with Invizius, a clinical-stage biotechnology ...

The story of Q32 Bio, a company that develops therapeutics for inflammatory and autoimmune diseases, started two decades ago. That's when V. Michael Holers, MD, a University of Colorado School of ...